Combined treatment of Ewing sarcoma with BRD- and CDK9-inhibitors resulted in enhanced responses compared to individual drugs in vitro and in a preclinical mouse model in vivo [69]. This evidence concerns the gene CDK9 and Ewing sarcoma.